Vittorio Cristini – författare

Mathematical modeling, analysis and simulation are set to play crucial roles in explaining tumor behavior, and the uncontrolled growth of cancer cells over multiple time and spatial scales. This book, the first to integrate state-of-the-art numerical techniques with experimental data, provides an in-depth assessment of tumor cell modeling at multiple scales. The first part of the text presents a detailed biological background with an examination of single-phase and multi-phase continuum tumor modeling, discrete cell modeling, and hybrid continuum-discrete modeling. In the final two chapters, the authors guide the reader through problem-based illustrations and case studies of brain and breast cancer, to demonstrate the future potential of modeling in cancer research. This book has wide interdisciplinary appeal and is a valuable resource for mathematical biologists, biomedical engineers and clinical cancer research communities wishing to understand this emerging field.

Physical oncology has the potential to revolutionize cancer research and treatment. The fundamental rationale behind this approach is that physical processes, such as transport mechanisms for drug molecules within tissue and forces exchanged by cancer cells with tissue, may play an equally important role as biological processes in influencing progression and treatment outcome. This book introduces the emerging field of physical oncology to a general audience, with a focus on recent breakthroughs that help in the design and discovery of more effective cancer treatments. It describes how novel mathematical models of physical transport processes incorporate patient tissue and imaging data routinely produced in the clinic to predict the efficacy of many cancer treatment approaches, including chemotherapy and radiation therapy. By helping to identify which therapies would be most beneficial for an individual patient, and quantifying their effects prior to actual implementation in the clinic, physical oncology allows doctors to design treatment regimens customized to each patient’s clinical needs, significantly altering the current clinical approach to cancer treatment and improving the outcomes for patients.